Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Viberzi

Chemical Nameeluxadoline
Dosage FormTablet (oral; 75 mg, 100 mg)
Drug Classmu-opioid receptor agonist
SystemDigestive
CompanyAllergan
Approval Year2015

Indication

  • For treatment of adults with irritable bowel syndrome with diarrhea (IBS-D).
Document TitleYearSource
Viberzi (eluxadoline) Prescribing Information.2020Allergan USA, Inc., Madison, NJ
Document TitleYearSource
Efficacy of opioid receptor modulators in patients with irritable bowel syndrome: a systematic review and meta-analysis.2021Medicine
Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis.2021Neurogastroenterology & Motility
Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.2020Gut
Australian public assessment report for eluxadoline. 2018Australian Government: Department of Health
Clinical review report: eluxadoline (Viberzi).2018CADTH
Document TitleYearSource
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.2022Gastroenterology
Evidence-based clinical practice guidelines for irritable bowel syndrome 2020.2021Journal of Gastroenterology
Canadian Association of Gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS).2020Journal of the Canadian Association of Gastroenterology
Drug updated on 6/12/2023

More on this drug: Clinical Trials